



SPEAKER'S BIOGRAPHY

NAME: Too Heng Phon

POSITION & AFFILIATION:

Assoc. Professor, Biochemistry Department,
NUS Centre for Cancer Research (N2CR),
Yong Loo Lin School of Medicine,
National University of Singapore

EMAIL ADDRESS: bchtoohp@nus.edu.sg



TITLE OF TALK: “From Bench to Bedside to Business” – Translating Research into Impact.
A personal experience in Singapore

PROFESSIONAL EXPERIENCE

Dr Too received his undergraduate training in Biochemistry, Imperial College of Science & Technology, UK. He then continued with his PhD training in a joint research project in Imperial College, Institute of Ophthalmology and West Minister Hospital, London.

Thereafter, he received further training in the Medical Research Council, Cambridge (UK), where he was a Procter & Gamble Fellow. He then moved to the Department of Anesthesiology and Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School where he was a recipient of the Merck Sharpe Dohme Academic Development Fellowship. Currently, he is a faculty of the Department of Biochemistry and Director of Research (N2CR), Yong Loo Lin School of Medicine, National University Singapore and a member of the expert advisor panel, Singapore Translational Cancer Consortium.

He was a Scientific Advisor to the Biotransformation Innovation Platform and a Scientist in the Bioprocess Technological Institute, A*STAR. He was also a Fellow of the Singapore Massachusetts Institute of Technology Alliance in the Molecular Engineering of Biological & Chemical Systems program and co-chaired the Chemical & Pharmaceutical Engineering program. His laboratory was funded by Roche Diagnostics (USA/Asia Pacific) and National Institute of Health (USA) to develop diagnostic assays.

There are intellectual property protections of diagnostic and biotechnology platforms with various agencies and with Massachusetts Institute of Technology, USA. Recently, his team



UHM UNIVERSITI
SAINS
MALAYSIA



**Molecular Diagnostics
& Biomarker Discovery**
Conference and Exhibition

MDBD | 3-4 October 2024 | Advancing Medical Health Technology | mdbd@usm.my

co-founded a non-viral gene delivery technology startup (AGeM Pte Ltd) to precision engineer mesenchymal stem cells as biopharmacy for oncology and regenerative medicine.

He is also a co-founder and non-executive chairman of MirXES Pte Ltd, a molecular diagnostic company.

AWARDS AND RECOGNITION

Dr Too is a recipient of the Singapore President's Technology Award 2021.

RESEARCH INTEREST

Dr Too is a passionate and dedicated expert in MicroRNA, Diagnostics, Gene Delivery, Stem Cells, Bioanalytics, Metabolic Engineering. He is a valuable asset to the diagnostics and therapeutics industry and is committed to making a difference in these areas.